Complexes of Streptavidin-Fused Antigens with Biotinylated Antibodies Targeting Receptors on Dendritic Cell Surface: A Novel Tool for Induction of Specific T-Cell Immune Responses

被引:6
|
作者
Stanek, Ondrej [1 ,2 ]
Linhartova, Irena [1 ]
Majlessi, Laleh [3 ,4 ]
Leclerc, Claude [3 ,4 ]
Sebo, Peter [1 ]
机构
[1] ASCR Vvi, Lab Mol Biol Bacterial Pathogens, Inst Microbiol, Prague 14220, Czech Republic
[2] Inst Chem Technol, CR-16628 Prague, Czech Republic
[3] Inst Pasteur, Unite Regulat Immunitaire & Vaccinol, F-75724 Paris, France
[4] INSERM, U1041, F-75015 Paris, France
关键词
Streptavidin; Antigen delivery; Biotinylated antibody; T-cell response; Dendritic cell; Receptor targeting; MYCOBACTERIUM-TUBERCULOSIS; CORE-STREPTAVIDIN; FUSION PROTEIN; IN-VIVO; ESAT-6-CFP-10; COMPLEX; PRESENTING CELLS; DEC-205; RECEPTOR; DRUG-DELIVERY; BONE-MARROW; VACCINATION;
D O I
10.1007/s12033-011-9459-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The choice of tools that enable efficient targeting of exogenous antigens (Ag) for processing and presentation by professional Ag-presenting cells (APC) remains limited. This represents, indeed, a bottleneck in development of vaccines inducing specific T-cell responses. Here, we describe a novel strategy of Ag delivery into APCs. The Ag of choice is fused to the N- or C-terminus of streptavidin (SA) and tetrameric Ag-SA or SA-Ag fusion proteins are produced in E. coli and purified by 2-Iminobiotin-Agarose affinity chromatography. Alternatively, Ag-SA proteins are purified from urea extracts of E. coli inclusion bodies and refolded in vitro into functional tetramers. Complexes with biotinylated antibodies targeting cell surface receptors are formed and used to deliver the Ags of choice for processing and presentation by APCs and induction of Ag-specific CD4(+) and CD8(+) T-cell responses in vitro and in vivo.
引用
收藏
页码:221 / 232
页数:12
相关论文
共 50 条
  • [31] Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture
    Guardo, Alberto C.
    Ruiz-Riol, Marta
    Fernandez, Emma
    Maleno, Maria J.
    Bargallo, Manel E.
    Leon, Agathe
    Climent, Nuria
    Garcia, Felipe
    Gatell, Jose M.
    Brander, Christian
    Plana, Montserrat
    AIDS, 2015, 29 (11) : 1309 - 1318
  • [32] DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses
    Shi, Liyun
    Luo, Kun
    Xia, Dajing
    Chen, Taoyong
    Chen, Guoyou
    Jiang, Yingming
    Li, Nan
    Cao, Xuetao
    BLOOD, 2006, 108 (08) : 2678 - 2686
  • [33] Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses
    Dangaj, Denarda
    Lanitis, Evripidis
    Zhao, Aizhi
    Joshi, Shree
    Cheng, Yi
    Sandaltzopoulos, Raphael
    Ra, Hyun-Jeong
    Danet-Desnoyers, Gwenn
    Powell, Daniel J., Jr.
    Scholler, Nathalie
    CANCER RESEARCH, 2013, 73 (15) : 4820 - 4829
  • [34] Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses
    Cao Dai Phung
    Thanh Tung Pham
    Hanh Thuy Nguyen
    Tien Tiep Nguyen
    Ou, Wenquan
    Jeong, Jee-Heon
    Choi, Han-Gon
    Ku, Sae Kwang
    Yong, Chul Soon
    Kim, Jong Oh
    ACTA BIOMATERIALIA, 2020, 115 : 371 - 382
  • [35] Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses
    Schiavo, Roberta
    Baatar, Dolgor
    Olkhanud, Purevdori
    Indig, Fred E.
    Restifo, Nicholas
    Taub, Dennis
    Biragyn, Arya
    BLOOD, 2006, 107 (12) : 4597 - 4605
  • [36] In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
    Lehmann, Steffi
    Perera, Ramanil
    Grimm, Hans-Peter
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Fahrni, Linda
    Schaller, Teilo
    Freimoser-Grundschober, Anne
    Zielonka, Jorg
    Stoma, Szymon
    Rudin, Markus
    Klein, Christian
    Umana, Pablo
    Gerdes, Christian
    Bacac, Marina
    CLINICAL CANCER RESEARCH, 2016, 22 (17) : 4417 - 4427
  • [37] Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer
    Kono, Koji
    Mizukami, Yoshiki
    Daigo, Yataro
    Takano, Atsushi
    Masuda, Ken
    Yoshida, Koji
    Tsunoda, Takuya
    Kawaguchi, Yoshihiko
    Nakamura, Yusuke
    Fujii, Hideki
    CANCER SCIENCE, 2009, 100 (08) : 1502 - 1509
  • [38] Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response
    Westerlind, Ulrika
    Hobel, Alexandra
    Gaidzik, Nikola
    Schmitt, Edgar
    Kunz, Horst
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (39) : 7551 - 7556
  • [39] Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: Biochemical probes for analysis and modulation of immune responses
    Lebowitz, MS
    O'Herrin, SM
    Hamad, ARA
    Fahmy, T
    Marguet, D
    Barnes, NC
    Pardoll, D
    Bieler, JG
    Schneck, JP
    CELLULAR IMMUNOLOGY, 1999, 192 (02) : 175 - 184
  • [40] Ex vivo induction of multiple myeloma-specific T-cell responses by dendritic cells stimulated by whole-tumour antigen of autologous myeloma cells
    Vasileiou, S.
    Baltadakis, I.
    Delimpasi, S.
    Karatza, M.
    Manaka, A.
    Liapis, K.
    Papageorgiou, M.
    Garofalaki, M.
    Tziotziou, E.
    Poulopoulou, Z.
    Nikolou, E.
    Bika, E.
    Apostolidis, J.
    Karakasis, D.
    Harhalakis, N.
    Bourantas, K.
    Nikiforakis, E.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S313 - S313